(NASDAQ: FBLG) Fibrobiologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.07%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31%.
Fibrobiologics's earnings in 2026 is -$18,139,000.On average, 3 Wall Street analysts forecast FBLG's earnings for 2026 to be -$20,374,071, with the lowest FBLG earnings forecast at -$19,575,087, and the highest FBLG earnings forecast at -$20,973,308. On average, 3 Wall Street analysts forecast FBLG's earnings for 2027 to be -$22,071,910, with the lowest FBLG earnings forecast at -$21,206,345, and the highest FBLG earnings forecast at -$22,721,084.
In 2028, FBLG is forecast to generate -$27,165,427 in earnings, with the lowest earnings forecast at -$26,100,117 and the highest earnings forecast at -$27,964,411.